Knight Therapeutics Inc. (“Knight” or the “Company”) (TSX VENTURE:GUD) today announced that it has completed its previously announced offering to a syndicate of underwriters led by GMP Securities L.P. and including Cormark Securities Inc. (collectively, the “Underwriters”), pursuant to which the Underwriters have purchased, on a private placement basis, 21,428,580 special warrants (the “Special Warrants”) of the Company at a price of $3.50 per Special Warrant for aggregate gross proceeds to Knight of $75,000,030 (the “Offering”).

3487911 Canada Inc. (“3487911”), an entity controlled by the Company's President and Chief Executive Officer, Jonathan Ross Goodman, has purchased 6,052,739 Special Warrants under the Offering (approximately $21 million).

Each Special Warrant is exercisable into one common share in the capital of Knight (the “Common Shares”) for no additional consideration. The Special Warrants will be deemed to be exercised upon the expiry of the hold period applicable thereto, being the earlier of: (i) a date that is no later than the fifth business day after the date of issuance of a receipt for a final prospectus qualifying the issuance of Common Shares underlying the Special Warrants; and (ii) four months and one day following the date hereof. Knight has agreed to use its commercially reasonable efforts to file a prospectus qualifying the issuance of the Common Shares underlying the Special Warrants in all provinces of Canada where purchasers of Special Warrants are resident.

The proceeds of the Offering will be used to fund Knight's future growth as well as for general corporate purposes.

The Underwriters have been paid a commission equal to 5.0% of the gross proceeds from the Offering (other than from sales to 3487911 and certain other entities and directors and officers of the Company) and have been granted that number of compensation options to purchase Special Warrants or Common Shares of the Company as is equal to 2.0% of the total number of Special Warrants sold pursuant to the Offering (other than from sales to 3487911 and certain other entities and directors and officers of the Company), exercisable within one year from the closing of the Offering at an exercise price equal to $3.75 per common share.

The securities that were sold have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

When commenting on the financing Jonathan Ross Goodman stated “We are grateful to have so many Knight supporters from the onset. We will not take this support for granted. This financing provides a key building block for Knight's sustained growth.”

Along with 3487911, certain members of management and the Board of Directors of Knight participated in the Offering. Participation of these insiders in the Offering constitutes a “related party transaction” as defined in the Regulation 61-101 respecting protection of minority security holders in special transactions (“MI 61-101”). The Offering is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities issued to insiders nor the consideration for such securities by insiders will exceed 25% of the Company's market capitalization. The Company did not file a material change report 21 days prior to closing of the Offering as the details of the participation of insiders of the Company in the Offering had not been confirmed at that time.

About Knight Therapeutics Inc.:

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares began trading on the TSX-V on March 3, 2014 under the symbol GUD. For more information about Knight Therapeutics, please visit the Company's web site at or at

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the Company's final application for listing on the TSX Venture Exchange and can be found on SEDAR at, which investors should consult for additional information. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.